ABSTRACT
Diseases of the nervous system, such as Alzheimer’s disease (AD) and brain cancer, seriously affect many people worldwide. In particular, Alzheimer’s disease is a progressive mental disorder and the leading cause of dementia characterized by memory loss and cognitive impairment in people over age 65 (Andreasen and Blennow 2002). Alzheimer’s disease is currently the third most highly occurring and expensive disease following cancer and cardiocerebral vascular diseases. There have been no non-invasive early diagnostic methods for most of these diseases until now. Related biomolecules will be present in cerebrospinal fl uid, blood or other body fl uids even before symptoms appear and these biomolecules, or biomarkers, are the most important early indicators of these diseases. Thus, the detection of biomarkers in biological fl uids for persons with high-risk is a promising diagnostic method. For example, amyloid beta derived diffusible ligands, ADDL, is a promising biomarker for AD and the detection of ADDL in biological fl uids has been used widely in the diagnosis of AD (Andreasen and Blennow 2002).
